Terms ending in 2038
Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,953,019 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity In force · High confidence | Ucb Biopharma SRL (Societe a Responsabilite Limitee) | In force | High confidence | |
| US 11,710,233 | Three-Dimensional Medical Image Analysis Method and System for Identification of Vertebral Fractures In force · Low confidence | Ucb Pharma SRL | In force | Low confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.